Thread by @RiyaSam12

#AHA23 LBCTs one liners:

1. SELECT: Among patients w/ overweight or obesity + established CVD w/o DM once-weekly SQ SEMAGLUTIDE was associated with a decreased risk of MACE comprised of CV death, nonfatal MI, and stroke compared with placebo

2.DAPA-MI: Among patients with acute MI w/o a hx of DM or c/c HF, DAPAGLIFLOZIN has better cardiometabolic outcomes compared with placebo, with no difference in CV outcomes.

3. MINT: Among patients w/ acute MI and anemia (Hgb <10 g/dL), a liberal transfusion goal (Hgb ≥10 g/dL) was not superior to a restrictive strategy (Hgb 7-8 g/dL) wrt 30-day all-cause death and recurrent MI.

4. ORBITA-2: Among patients w/ stable angina & coronary stenoses causing ischemia on no antianginal therapy, PCI results in greater improvements in anginal frequency and exercise times compared with a sham procedure.

5. ARIES HM3:  Among patients w/ advanced HF who received a HeartMate 3 LVAD and were anticoagulated with a VKA, placebo was non-inferior to daily aspirin with respect to the composite endpoint of bleeding and thrombotic events at 1 year.

6. TEAMMATE: Among children/young adults w/ cardiac transplantation, everolimus with low-dose tacrolimus compared with tacrolimus with mycophenolate was safe when initiated 6 mo after cardiac transplant.

7. CRHCP: In patients with HTN in rural China, the primary outcome of all-cause dementia was significantly reduced by 15% in the intensive BP lowering group compared to the usual care group at 48 mo.

8. POP-HT: Self-monitoring and physician-guided titration of antiHTN medications was associated w lower BP during the first 9 mo postpartum than usual postnatal outpatient care in the UK.

9. CARDIA-SSBP: In a community-based cohort of middle aged patients, a low Na diet was associated w/ a median 7 mm Hg reduction in SBP, regardless of HTN status or anti-HTN drug use

10. KARDIA-1: Among patients w/ HTN, the novel SQ injectable ZILEBESIRAN improves ambulatory and office SBP compared w/ placebo.

11. ARTESIA: Among patients w/ subclinical AF & increased risk for cva, APIXABAN reduced the risk of stroke/systemic embolism compared w/ aspirin.

12. AZALEA-TIMI 71: Among patients w/ AF and a high CHA2DS2VASc score. both the tested doses of ABELACIMAB (90 mg and 150 mg monthly) are superior to Rivaroxaban 20 mg daily in reducing bleeding events

13. NOAH-AFNET 6: In patients w/ implanted cardiac device-detected AHREs, EDOXABAN was not associated with decreased incidence of CV death, stroke, or systemic embolism but was associated with increased bleeding compared with placebo.

14. VERVE101: The first proof-of-concept for in vivo DNA base editing in humans shows a single infusion of a CRISPR-based gene editing therapy significantly reduces LDL-C and PCSK9 levels in patients with heterozygous FH.

15. Efficacy and Safety of Lepodisiran (Phase I): In 48 participants with elevated LP(a) levels, LEPODISIRAN was well tolerated with dose dependent, long duration reductions in serum LP(a) concentrations.

16. REMAIN-2: In patients w/ non-familial hypercholesterolemia and mixed HLD not controlled by moderate/high-intensity, add-on therapy with RECATICIMAB demonstrated dosage-dependent reduction in LDLc compared to placebo.

17. REPRIEVE: Among pts w/ HIV infection and low-to-moderate risk of CVD, PITAVASTATIN was beneficial and may be mediated by decreased risk of plaque progression, decreased lipid oxidation, and decreased arterial inflammation.

18. ESPRIT: Among Asian pts w/ HTN and a large proportion of DM & stroke, intensive BP control improves outcomes compared with standard control.

19. I-CLAS: Among patients undergoing CRT, LBBAP was associated w a lower incidence of sustained VT/VF & new-onset AF compared w BVP

20 SPEC-AI:  In pregnant/postpartum women, AI-guided screening with a digital stethoscope was associated with an increase in the diagnosis of cardiomyopathy defined as LVEF <50% by echocardiography.

21. SPEECH: In NYHA Class II/III HF outpatients, this study developed a speech processing model &validated a novel speech analysis app that detected future HF events early with a high sensitivity and low unexplained notification rate

22. ARISE: Among patients who received an ECG in the emergency department, AI-ECG shortens the time from ECG acquisition to arrival in the cath lab.

23. ReVeRA-201 phase 2: Among patients w Afib RVR, ETRIPAMIL nasal spray was associated w/ a rapid reduction in ventricular rates

24. ORFAN: AI-driven assessment of perivascular fat (FAI Score) to predict inflammatory risk as part of routine CCTA accurately predicted fatal and nonfatal cardiac events, independent from clinical risk scores and CT interpretation

25. ECLS-SHOCK: Among patients with acute MI, ECLS failed to improve 30-day survival and was also associated with safety concerns due to an increased incidence of moderate or severe bleeding.

26. STEP-HFpEF: Among obese patients w/ HFpEF, once weekly SQ SEMAGLUTIDE was superior to placebo in improving body weight and patient oriented QoL outcomes at 52 wks

27. Sodium-Glucose Cotransporter-2 Inhibitors in Transthyretin Amyloid Cardiomyopathy: SGLT2-i treatment in ATTR-CM patients was well tolerated and associated with less worsening of HF symptoms and NT-proBNP, slower decline in eGFR and lower diuretic requirement over time.

28. ATTRibute-CM: Among patients w/ ATTR-CM ACORDAMIS HCl is superior to placebo for improving both hard cardiovascular endpoints as well as QoL endpoints.

29. ARTICA: Pre-hospital rule-out of ACS with a POC troponin measurement in low-risk patients significantly reduces healthcare costs while the incidence of MACE was low in both strategies

30. STEROHCA: Prehospital treatment with high-dose Methylprednisolone reduced the need for NE while improving MAP values in resuscitated OHCA patients for the initial 48h of admission.

31. WATCHFUL: In patients with HFrEF, lifestyle intervention improved daily steps by about 25%, it failed to demonstrate a corresponding improvement in functional capacity.

32. The Jewel Investigational Device Exemption Study: The patient-centric Jewel P-WCD is a safe and effective WCD and led to high compliance, resulting in a high number of patient saves and no deaths due to non-compliance when compared to other WCDs.

33. Incidence and Causes of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-year Study: While the incidence of SCD in college athletes has decreased, Male sex, Black race, and basketball are associated with higher incidence of SCD.

34. LEAF:  In a group of obese patients with primarily PerAF, pre-ablation treatment with risk factor modification and/or RFM+LIRAGLUTIDE results in weight loss, and reduction in epicardial adipose tissue. Improved outcomes were observed from PVI ablation with RFM+L.

35. KABUKI: In CTEPH pts who had undergone reperfusion treatment and were on stable warfarin therapy, edoxaban was non-inferior to warfarin for preventing worsening of pulmonary hemodynamics during the 48 wks treatment.

36. STEMI: In patients with STEMI, IL-1 blockade with RPH-104, GOFLIKICEPT 80 mg or 160 mg significantly reduced CRP compared with placebo, and treatment with RPH-104 appears safe.

37. LIVE-LQTS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk-assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not.

38. EMPA-ICD: In patients w/ T2DM treated with ICD/CRT-D, Empagliflozin reduces the number of ventricular arrhythmias versus placebo.

39. FAST-MI: High-dose lipid lowering therapy at dc after AMI was associated w/ reduced all-cause mortality at 5 yrs in a geriatric population.

40. IMPACTS: Among low-income patients with hypertension who received healthcare at FQHC clinics, the multifaceted implementation strategy significantly improved BP control when compared to usual care.

41. HTN Treatment in Nigeria Program: Early Results of a Type 2 Hybrid Effectiveness & Implementation Interrupted Time Series Trial: A large-scale, multi-level HTN program led by community health extension workers improved HTN control in the federal capital territory.

42. SPECIAL: In patients w/ intermediate-high risk PE, USAT did not meet non-inferiority compared to surgical pulm embolectomy for early reversal of RV overload.

43. NICE: Among patients w PAD, Nicotinamide Riboside improved walking performance compared to placebo.

44. PROMINENT: In patients with T2D, mild-to-moderate hyperTG, and low levels of HDL on guideline-directed lipid-lowering therapy, PEMAFIBRATE significantly reduced the risk of LE ischemic ulceration or gangrene.

@AHAMeetings @AHAScience @ACCinTouch @UCNSCards @HeartOTXHeartMD @ErinMichos @DrMarthaGulati @AbhiKulk82